3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Terminated
1
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
5
Endocrine
5
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Gynecologic
1
Gastrointestinal
1
CNS
1
Conditions
Myelodysplastic Syndromes
24
Leukemia, Myeloid, Acute
23
Myeloproliferative Disorders
16
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
16
Polycythemia Vera
10
Primary Myelofibrosis
7
Thrombocythemia, Essential
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Leukemia, Myeloid, Chronic-Phase
4
Leukemia
4
Polycythemia
3
Lymphohistiocytosis, Hemophagocytic
3
Leukemia, Myelomonocytic, Chronic
3
Hematologic Neoplasms
3
Hematologic Diseases
3
Recurrence
2
Myelodysplastic-Myeloproliferative Diseases
2
Motor Activity
2
Lymphoproliferative Disorders
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Epstein-Barr Virus Infections
2
VEXAS syndrome
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Thrombophilia
1
Thrombocytosis
1
Thrombocytopenia
1
Polycythemia, primary familial and congenital
1
Pleural Effusion, Malignant
1
Interventions
trametinib
1
dabrafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Thyroid Carcinoma, Anaplastic
×
Myeloid
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled